Brief: Fulcrum Therapeutics Q4 Basic EPS USD -0.4
27/02/2024 12:00
Feb 27 (Reuters) - Fulcrum Therapeutics Q4 net income USD -24.756 million. * Q4 operating income USD -27.992 million vs. IBES estimate USD -29 million * Q4 collaboration revenue USD 871 thousand * Q4 operating expenses USD 28.863 million
Recent news on Fulcrum Therapeutics
See all newsFulcrum Therapeutics, Inc. expected to post a loss of 14 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE - Nvidia, Gold miners, Nike
U.S. STOCKS ON THE MOVE - Sunrun, JetBlue Airways, Dell Technologies
U.S. STOCKS ON THE MOVE - KBR, Vista Energy, Fulcrum Therapeutics
Fulcrum to merge with Slate in all-stock deal after drug setback